Neurological Disorders and Stroke will be organized around the theme Creating a Future Map for Neurological Disorders and Stroke
stroke-2023 is compromised of 22 tracks and 0 sessions designed to offer comprehensive sessions that address current issues in stroke-2023
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
Neurological disorders encompass ailments affecting both the central and peripheral nervous systems. They encompass a range of conditions like malnutrition-induced neurological issues, epilepsy, Alzheimer's disease, other forms of dementia, cerebrovascular diseases like stroke, various headache disorders such as migraines, multiple sclerosis, Parkinson's disease, neuro infections, and brain tumors.
In recent days, there has been a significant impact of strokes on various individuals, even including infants. The stroke management market is segmented into hospitals, diagnostic centers, outpatient surgical centers, and other facilities. As of 2021, the hospital sector holds the largest market share, accounting for nearly 42 percent. Unfortunately, strokes claim the lives of numerous people. The prevention of strokes, different stroke types, and related disorders will be extensively discussed in the upcoming event, Stroke 2023. These stroke types encompass Brain stroke, pediatric stroke, Neonatal stroke, and Ischemic stroke.
During 2020, the global neuroscience market's value stood at $36.5 billion. Moving forward, IMARC Group anticipates a steady growth trajectory, projecting a compound annual growth rate (CAGR) of 4.1% from 2022 to 2028, with an estimated value of $46.2 billion by 2031. The field of neurology is continuously progressing, marked by continuous research and the development of novel treatments and therapies. Advancements in neuroscience and technology have significantly enhanced our comprehension of the brain and nervous system, unlocking fresh possibilities for diagnosing and treating neurological disorders.
Mental health has emerged as a critical market in recent years, driven by increasing awareness and destigmatization. The demand for mental health services, therapies, and medications is on the rise due to the growing prevalence of mental health issues worldwide. Technological advancements in telemedicine and digital mental health solutions have also played a significant role in expanding the market and improving access to care. However, challenges remain, including access barriers and the need for further investment in research and treatment options.
In recent years Animal models Testing was such a trending topic in Neurology. The market for animal models was valued at USD 17.27 billion in 2019 and is anticipated to rise to USD 29.08 billion by 2025, at a CAGR of 10.29%. Neuroscience, pharmacology, toxicology, and genetics are just a few of the scientific areas that employ animal models. Animals including mice, rats, rabbits, dogs, and non-human primates are frequently utilized as models those will be briefly elaborated in Stroke Conference.
Alzheimer's disease is a neurodegenerative disorder that affects the brain, causing a decline in cognitive function and memory loss. In older people, it is the most typical cause of dementia. The Global market rate for Alzheimer’s disease was estimated to be worth $4.3 billion in 2019 and $6.2 billion by 2023, with a CAGR of 6.3% during the period of 2019-2023.
Tremors, stiffness, bradykinesia (slow movement), and postural instability are all signs of Parkinson's disease. Other symptoms may include a loss of smell, sleep disturbances, constipation, depression, and cognitive impairment. The market for medications for Parkinson's disease was estimated to be worth $5.9 billion globally in 2020; it is anticipated to increase to $11.2 billion by 2028, with a CAGR of 6.8% from 2020 to 2035. Parkinson's disease is a neurodegenerative condition commonly known as idiopathic Parkinsonism.
Epilepsy remains a significant market with a high demand for innovative therapies. As one of the most prevalent neurological disorders globally, it affects millions of individuals, creating a substantial need for advanced diagnostics and treatments. The market is driven by ongoing research, pharmaceutical investments, and the rising adoption of digital health technologies.
Peripheral nervous system disease called Guillain-Barre syndrome. During the projection period, 2021-2026, the Guillain-Barre Syndrome Market Study is expected to expand at a CAGR of 4.9%. The COVID-19 virus has a substantial effect on the market for Guillain-Barre syndrome (GBS) treatments.
Dementia falls under the category of neurological disorders, encompassing a range of symptoms that notably impact memory, cognitive abilities, and social skills. When these symptoms significantly disrupt daily functioning, they are referred to as dementia. Various conditions can lead to dementia, without necessarily being linked to a single specific disease.
Ischemic stroke, commonly known as a brain stroke, occurs when a certain area of the brain experiences a blockage or reduction in blood flow, leading to a deprivation of oxygen and nutrients to the brain tissue. This condition causes the brain cells to start deteriorating within minutes. In recent times, numerous individuals have been affected by ischemic stroke due to insufficient blood supply to the brain.
The Global Brain Tumor Market is set to experience significant growth, starting at USD 2.8 billion in 2022 and reaching an impressive USD 6.5 billion by 2032. In the same period, the global oncology market is projected to expand from USD 208 billion in 2022 to USD 628 billion by 2032, with a steady compound annual growth rate (CAGR) of 12% over the decade.
For neonatal and pediatric stroke, respectively, the average adjusted 5-year expenditures are significant at $54,719 and $135,168. The average price of admission for a youngster with a stroke was $91,869. Neonatal stroke birth admission expenses were on average $49,633; when these prices were adjusted for control birth admission costs, the difference was just $5,792, indicating that the stroke was responsible for 87% of the expenditures.
Treatment for Cerebrovascular disease depends on the underlying condition and the severity of the symptoms. Medications may be used to help prevent blood clots and reduce the risk of stroke or TIA, and surgery or endovascular procedures may be necessary to repair damaged blood vessels or prevent further damage. Cerebrovascular disease knowledge was very important these are briefly elaborated on the Stroke 2023.
The market for neurodegenerative diseases was estimated to be worth USD 39,125 million in 2020, and it is anticipated to grow to USD 78,295 million by 2035, showing a CAGR of 6.2% during the projected period (2020–2035).
The market for treatments for transthyretin amyloidosis was valued at USD 4.822 billion in 2020 and is projected to grow to USD 7.11 billion by 2025. The size of the worldwide market for amyloidosis treatments was estimated at USD 3.7 billion in 2018 and is projected to grow at a CAGR of 6.9% during the forecast period. Some of the reasons that will jointly drive the market are the expanding elderly population, the increased acceptance of innovative targeted treatments and transplantation, the introduction of biologics, and these.
Neuroimaging and neurosonology are both diagnostic tools used in the field of neurology to help visualize and study the structure and function of the brain and nervous system. Neuroimaging refers to a group of techniques used to create images of the brain and its structures. Neurosonolgy is one of the diagnostic tools that use ultrasound technology.
Contemporary Neuroscience comprises various branches, encompassing affective neuroscience, behavioral neuroscience, cellular neuroscience, clinical neuroscience, cognitive neuroscience, cultural neuroscience, molecular neuroscience, and social neuroscience.
This market research study on the treatment of dementia and movement disorders offers insightful information on the market's response to COVID-19, which will assist businesses in assessing their strategic business plans. The researcher at Technavio projects that the market for treating dementia and mobility disorders would be worth USD 8.14 billion by 2030, growing at a CAGR of 7.95%.
The protective coating known as the myelin sheath, which covers nerve fibers in the central and peripheral nervous systems, is a structure that is harmed by a set of illnesses known as demyelinating diseases. Numerous symptoms, including muscular weakness, tingling or numbness in the limbs, issues with balance and coordination, as well as issues with vision and speech, can be brought on by these illnesses.
Depending on the underlying reason, treatment for cognitive impairment may involve drugs to control symptoms, cognitive and behavioral therapy, lifestyle changes, and supportive care. Early detection and treatment of cognitive impairment are crucial because certain causes of it may be reversible if discovered and addressed quickly enough. The cognitive impairment will be explained in Stroke 2023.
A specialty of medicine called pediatric neurology is dedicated to identifying and treating neurological disorders in infants and children. Pediatric neurologists are medical professionals with specialized training in this area who are prepared to treat newborns, kids, and teenagers with neurological issues.
Neurotherapy, also known as neurofeedback or EEG biofeedback, is a type of therapy that uses real-time feedback from the brain to help individuals learn to regulate and control their brainwave activity. The market for Neurotherapy is anticipated to reach $ 1,236.6 million in 2021 and grow at a CAGR of 7.4% from 2021 to 2027.
Stroke rehabilitation is a growing market due to the increasing prevalence of strokes. Demand for specialized therapies, medical devices, and home-based solutions is rising. Technological advancements, aging populations, and healthcare investments are driving this market's growth, presenting opportunities for innovative solutions and improved patient outcomes.
Autism, a neurodevelopmental disorder, is characterized by challenges in social interaction, communication, and repetitive behaviors. It varies in severity, and early diagnosis and intervention are crucial for better outcomes. Autism's exact cause remains unclear, but research and awareness continue to grow, promoting understanding and support for individuals on the spectrum.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
